Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial
Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.
Source: onclive.com
Page 13 - Recent Updates News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Recent Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Recent Updates Today - Breaking & Trending Today
ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS
Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.
Source: onclive.com
Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches
Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.
Source: onclive.com
The Role of Adjuvant Therapy in Patients With Early-Stage HCC
Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.
Source: onclive.com
Bispecifics in Multiple Myeloma: Dosing and Transition of Care
A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.
Source: onclive.com